Celgene enters $2.5B deal with Jounce for cancer immunotherapy research

Jounce Therapeutics entered into a $2.5 billion investment agreement with Summit, N.J.-based Celgene to develop a new immunotherapy drug, according to Reuters.

Jounce's drug, called JTX-2011, helps stimulate the immune system to fight off cancer. The company is targeting biological markers on tumors, hoping to provide more specific, individualized therapy matches for patients.

The Cambridge, Mass.-based company will receive $225 million upfront from Celgene for an option to jointly develop JTX-2011, among other new treatments. Additionally, Celgene will invest $36 million in Jounce for a minority stake.

Jounce, which was founded three years ago and only has 60 employees, could earn up to $2.3 billion in further milestone payments.

The company expects to start clinical trials for JTX-2011 later this year.

More articles on the drug market:

FDA approves Aurobindo's new pain med
Roche's blood cancer drug disappoints in clinical trial
PhRMA adds 5 new companies to its ranks, including generic rival Teva

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars